RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 57-61

  Quedas, Elisangela P S ^a   Longuini, Viviane C ^a   Sekiya, Tomoko ^a   Coutinho, Flavia L ^a   Toledo, Sergio P A ^a   Tannuri, Uenis ^a   Toledo, Rodrigo A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Haplotypes; Hirschsprung; HSCR; MEN2; RET

Indexed keywords

PROTEIN RET;

GENETICS; GENOTYPE; HAPLOTYPE; HIRSCHSPRUNG DISEASE; HUMAN; MEDULLARY CARCINOMA; MUTATION; REVIEW; SIPPLE SYNDROME; THYROID TUMOR;

CARCINOMA, MEDULLARY; GENOTYPE; GERM-LINE MUTATION; HAPLOTYPES; HIRSCHSPRUNG DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 84863911857     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)11     Document Type: Review

References (35)

1. Amiel J, Lyonnet S. Hirschsprung disease, associated syndromes, and genetics: a review. J Med Genet. 2001;38(11):729-39, http://dx.doi.org/10.1136/jmg.38.11.729.
2. Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, et al. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet. 2008;45(1):1-14, http://dx.doi.org/10.1136/jmg.2007.053959.
3. Moore SW, Zaahl M. The Hirschsprung's-multiple endocrine neoplasia (MEN) connection. Clinics. 2012;67(S1):63-7, http://dx.doi.org/10.6061/clinics/2012(Sup01)12.
4. Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr. 1982;1(4):603-7, http://dx.doi.org/10.1097/00005176-198212000-00027.
5. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, et al. Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet. 1994;3(12):2163-7, http://dx.doi.org/10.1093/hmg/3.12.2163.
6. Borst MJ, VanCamp JM, Peacock ML, Decker RA. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery. 1995;117(4):386-91, http://dx.doi.org/10.1016/S0039-6060(05)80057-1.
7. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA. 1996;276(19):1575-9, http://dx.doi.org/10.1001/jama.1996.03540190047028.
8. Caron P, Attié T, David D, Amiel J, Brousset F, Roger P, et al. C618R mutation of exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab. 1996;81(7):2731-3, http://dx.doi.org/10.1210/jc.81.7.2731.
9. Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, et al. Cys618Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat. 1997;10(2):155-9, http://dx.doi.org/10.1002/(SICI)1098-1004(1997)10:2,155::AIDHUMU7.3.0. CO;2-J.
10. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab. 1998;89(9):3361-4, http://dx.doi.org/10.1210/jc.83.9.3361.
11. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotypephenotype correlation. Hum Mol Genet. 1998;7(1):129-34, http://dx.doi.org/10.1093/hmg/7.1.129.
12. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MK, Lairmore TC, et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg. 2002;235(5):648-55, http://dx.doi.org/10.1097/00000658-200205000-00006.
13. Toledo SP, dos Santos MA, Toledo RA, Lourenço DM Jr. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics. 2006;61(1):59-70, http://dx. doi.org/10.1590/S1807-59322006000100011.
14. Tannuri U, Tannuri AC. Congenital megacolon in the newborn: which is the best treatment? Rev Assoc Med Bras. 2007;53(2):100-1, http://dx.doi.org/10.1590/S0104-42302007000200008.
15. Coelho MC, Tannuri U, Benditt I, Santos MM. Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprung"s disease. Pediatr Surg Int. 2008;24(9):1017-21, http://dx.doi.org/10.1007/s00383-008-2207-8.
16. Santos MM, Tannuri U, Coelho MC. Study of acetylcholinesterase activity in rectal suction biopsy for diagnosis of intestinal dysganglionoses: 17-year experience of a single center. Pediatr Surg Int. 2008;24(6):715-9, http://dx.doi.org/10.1007/s00383-008-2141-9.
17. Tannuri AC, Tannuri U, Romão RL. Transanal endorectal pull-through in children with Hirschsprung's disease: technical refinements and comparison of results with the Duhamel procedure. J Pediatr Surg. 2009;44(4):767-72, http://dx.doi.org/10.1016/j.jpedsurg.2008.08.002.
18. Machens A, Lorenz K, Dralle H. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid carcinoma. J Intern Med. 2009;266(1):114-25, http://dx.doi.org/10.1111/j.1365-2796.2009.02113.x.
19. Machens A, Dralle H. Multiple endocrine neoplasia type 2: achievements and current challenges. Clinics. 2012;67(S1):113-8, http://dx.doi.org/10.6061/clinics/2012(Sup01)19.
20. Correia-Deur JE, Toledo RA, Imazawa AT, Lourenço DM Jr, Ezabella MC, Tavares MR, et al. Sporadic medullary thyroid carcinoma: clinical data from a university hospital. Clinics (Sao Paulo). 2009;64(5):379-86, http://dx.doi.org/10.1590/S1807-59322009000500002.
21. Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo). 2009;64(7):699-6, http://dx.doi.org/10.1590/S1807-59322009000700015.
22. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mut. 2011;32(1):51-8, http://dx.doi.org/10.1002/humu.21385.
23. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J. 2000;19(15):4056-63, http://dx.doi.org/10.1093/emboj/19.15.4056.
24. Nishikawa M, Murakumo Y, Imai T, Kawai K, Nagaya M, Funahashi H, et al. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease. Eur J Hum Genet. 2003;11(5):364-8, http://dx.doi.org/10.1038/sj.ejhg.5200971.
25. Pasini B, Borrello MG, Greco A, Bongarzone I, Luo Y, Mondellini P, et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet. 1995;10(1):35-40, http://dx.doi.org/10.1038/ng0595-35.
26. Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Atti T, et al. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J Clin Invest. 1998;101(6):1415-23, http://dx.doi.org/10.1172/JCI375.
27. Carlomagno F, De Vita G, Berlingieri MT, De Franciscis V, Mellilo RM, Colantuoni V, et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. EMBO J. 1996;15(11):2717-25.
28. Iwashita T, Murakami H, Asai N, Takahashi M. Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extra cellular domain. Hum Mol Genet. 1996;5(10):1578-80, http://dx.doi.org/10.1093/hmg/5.10.1577.
29. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med. 1998;243(6):515-20, http://dx.doi.org/10.1046/j.1365-2796.1998.00332.x.
30. Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A. Genome-wide association study in Mennonites identifies multiple genes for oligogenic Hirschsprung disease. Am J Hum Genet. 2002;71(1):193-7, http://dx.doi.org/10.1086/341345.
31. Borrego S, Wright FA, Fernández RM, Williams N, Lopez-Alonso M, Davuluri R, et al. A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. Am J Hum Genet. 2003;72(1):88-100, http://dx.doi.org/10.1086/345466.
32. Fernández RM, Antiñolo G, Eng C, Borrego S. The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Hum Mut. 2003;22(5):412-5, http://dx.doi.org/10.1002/humu.10273.
33. Ruiz-Ferrer M, Torroglosa A, Luzón-Toro B, Fernandez RM, Antinolo G, Mulligan LM, et al. Novel mutations at RET ligand genes preventing receptor activation are associated to Hirschsprung's disease. J Mol Med (Berl). 2011;89(5):471-80, http://dx.doi.org/10.1007/s00109-010-0714-2.
34. Carniti C, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, et al. The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease. Am J Pathol. 2006;168(4):1262-75, http://dx.doi.org/10.2353/ajpath.2006.050607.
35. Toledo RA, Wagner SM, Coutinho FL, Lourenço DM Jr, Azevedo JA, Longuini VC, et al. High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab. 2010;95(3):1318-27, http://dx.doi.org/10.1210/jc.2009-1355.